BACKGROUND: Sarcoidosis is a systemic granulomatous disease of unknown etiology. The presence of mycobacterial nucleic acid components in patients with sarcoidosis has been demonstrated with varying degrees of success. OBJECTIVES: The aim of this study was to estimate the presence of Mycobacterium tuberculosis DNA in tissues from sarcoidosis patients, in Catalonia, Spain, as well as to assess the long-term clinical course in these patients. METHODS: Fifty-eight paraffin-embedded tissue biopsies corresponding to cases of sarcoidosis (n = 23), lung neoplasm (n = 23), and lung tuberculosis (n = 12) available in 1996 were analyzed in a retrospective study by means of a nested polymerase chain reaction using primers corresponding to the insertion element IS6110 of M. tuberculosis complex. For greater sensitivity, Southern blot hybridization was performed. Clinical data were recorded prior to and after PCR analysis (follow-up reported until 2002). RESULTS: M. tuberculosis DNA was present in 9 out of 23 sarcoidosis biopsies (39%), in 1 out of 23 control patients (4%) (p < 0.01), and in all tissue samples from the 12 control patients with tuberculosis. To date, none of these sarcoidosis patients has developed tuberculosis over a mean (+/-SD) follow-up period of 11 (+/-3.4) years. CONCLUSION: In our setting, M. tuberculosis DNA is present in tissue biopsies of significantly more sarcoidosis patients than controls. However, these results do not demonstrate causality, although they may suggest a link between M. tuberculosis infection and sarcoidosis in some cases. Follow-up of these patients suggests that M. tuberculosis-DNA-positive sarcoidosis patients are not at greater risk of developing tuberculosis than M. tuberculosis-DNA-negative patients. Copyright 2006 S. Karger AG, Basel.
BACKGROUND:Sarcoidosis is a systemic granulomatous disease of unknown etiology. The presence of mycobacterial nucleic acid components in patients with sarcoidosis has been demonstrated with varying degrees of success. OBJECTIVES: The aim of this study was to estimate the presence of Mycobacterium tuberculosis DNA in tissues from sarcoidosispatients, in Catalonia, Spain, as well as to assess the long-term clinical course in these patients. METHODS: Fifty-eight paraffin-embedded tissue biopsies corresponding to cases of sarcoidosis (n = 23), lung neoplasm (n = 23), and lung tuberculosis (n = 12) available in 1996 were analyzed in a retrospective study by means of a nested polymerase chain reaction using primers corresponding to the insertion element IS6110 of M. tuberculosis complex. For greater sensitivity, Southern blot hybridization was performed. Clinical data were recorded prior to and after PCR analysis (follow-up reported until 2002). RESULTS:M. tuberculosis DNA was present in 9 out of 23 sarcoidosis biopsies (39%), in 1 out of 23 control patients (4%) (p < 0.01), and in all tissue samples from the 12 control patients with tuberculosis. To date, none of these sarcoidosispatients has developed tuberculosis over a mean (+/-SD) follow-up period of 11 (+/-3.4) years. CONCLUSION: In our setting, M. tuberculosis DNA is present in tissue biopsies of significantly more sarcoidosispatients than controls. However, these results do not demonstrate causality, although they may suggest a link between M. tuberculosis infection and sarcoidosis in some cases. Follow-up of these patients suggests that M. tuberculosis-DNA-positive sarcoidosispatients are not at greater risk of developing tuberculosis than M. tuberculosis-DNA-negative patients. Copyright 2006 S. Karger AG, Basel.
Authors: M Veltkamp; P A H M Wijnen; C H M van Moorsel; G T Rijkers; H J T Ruven; M Heron; O Bekers; A M E Claessen; M Drent; J M M van den Bosch; J C Grutters Journal: Clin Exp Immunol Date: 2007-06-12 Impact factor: 4.330
Authors: Isaac Brownell; Francisco Ramírez-Valle; Miguel Sanchez; Stephen Prystowsky Journal: Am J Respir Cell Mol Biol Date: 2011-06-09 Impact factor: 6.914
Authors: M Veltkamp; C H M Van Moorsel; G T Rijkers; H J T Ruven; J M M Van Den Bosch; J C Grutters Journal: Clin Exp Immunol Date: 2010-08-19 Impact factor: 4.330